Hefei Biological and Pharmaceutical Industry's Annual Revenue Exceeds One Billion Yuan

(Source: Market Star News)

Star News reports that Hefei’s biopharmaceutical industry will deliver an impressive performance by 2025: over 1,000 blockchain-based companies, annual revenue exceeding 100 billion yuan, and manufacturing output increasing by 5.8% year-on-year.

It is learned that Hefei’s biopharmaceutical enterprise ranks are continuously expanding. Currently, the city has 10 listed companies in the biopharmaceutical sector, over 500 “above-scale” enterprises, and the number of industrial enterprises above designated size has increased by 37.8% year-on-year.

By 2025, Hefei’s innovative drug and medical device R&D has seen frequent breakthroughs: Qihai Medical’s biodegradable nasal and ear hemostatic sponge became the only product in the province to pass the national special review process for innovative medical devices; Anke Biological’s AK2024 injection became the world’s first approved clinical innovative HER2 monoclonal antibody drug…

It is reported that Hefei has established platforms such as the National Health Big Data Industrial Park and Yaogu Science and Technology Industrial Park, and set up the province’s first pilot zone for biopharmaceutical scientific and technological achievement transformation. The Chinese Academy of Sciences Clinical Research Hospital and the First Affiliated Hospital of Anhui Medical University have successively settled in, promoting clinical research results from “laboratory” to “shelf.” The first industrial chain integrated innovation measures in Anhui Free Trade Zone have been released, supporting Hefei’s biopharmaceutical industry’s high-quality development across the entire chain.

“We are implementing a ‘combination punch,’ providing comprehensive support from funding, policies, to scenarios,” said the head of the Pharmaceutical Industry Department at Hefei’s Bureau of Industry and Information Technology. “We aim to build a service system covering the entire lifecycle of biopharmaceutical enterprises, introduce special policies, establish a ‘fund jungle,’ promote a series of institutional innovations, and drive innovation results from samples to products, and from products to commodities, pushing Hefei’s biopharmaceutical industry towards new and better development.”